Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk

General condition age will be recorded.

Performance status by Eastern Cooperative Oncology Group (ECOG) Scale

Number of Participants With Substance abuse of tobacco and alcohol will be recorded.

Diagnosis of other primary tumors synchronous or metachronous, will be recorded.

BMI is a value derived from the mass (weight) and height. The BMI is defined as the body mass divided by the square of the body height, and is universally expressed in units of kg/m2, resulting from mass in kilograms and height in metres.

Primary comorbidities will be recorded.

Mutational status of BRCA or other genes of genetic predisposition will be recorded.

Family history of cancer will be recorded.

Date of diagnosis will be collected.

The histology of the tumor will be collected

Tumor clinical and/or pathological stage will be collected through the tumor-node-metastasis (TNM) staging system of the Union for International Cancer Control (UICC).

Hormone-receptor expression will be collected

Human Epidermal Growth Factor Receptor 2 (HER-2) expression will be collected

Tumor histologic grade will be collected

Tumor Ki-67 proliferation index will be collected

Number of Participants With Presence of lymphovascular invasion will be collected

Will be collected date of surgery

Number of participants with each type of surgery: mastectomy or lumpectomy or quadrantectomy or lymphadenectomy or sentinel lymph node biopsy will be collected.

Number of Participants With neoadjuvant chemotherapy and adjuvant chemotherapy.

Number of Participants With adjuvant radiotherapy

Number of Participants With hormonotherapy

Number of Participants With other type of anti-cancer treatment.

Number of Participants With each relapse type: local, regional or distant

Number of Participants With site of metastatic disease

Number of Participants With occurrence of other primary tumors whether or not of breast origin (in situ or invasive).

The date of the last review and current clinical condition will be recorded.

Number of Participants With tumor subtypes, luminal profiles (e.g., luminal subtypes M1/M2, intrinsic subtypes)

Number of Participants With risk groups on the reference of breast cancer in women, including morphological analyses and description of the clinical profile (e.g., morphological type, differentiation (histologic grade), Estrogen Receptor (ER), Progesterone Receptor (PgR), Human Epidermal growth factor Receptor 2 (HER2), Androgen Receptor (AR), Ki-67).

Date and cause of death, when applicable.

DFS: it is defined as the time from date of initial breast cancer diagnosis to the date of the first documented relapse event (local, regional and/or distant) of the disease, second breast or non-breast primary tumor, or death due to any cause, whichever occurs first. In the event that none of the previous events were observed, censoring the last contact date will be considered.

DMFS: it is defined as the time from date of initial breast cancer diagnosis to the date of the first documented distant relapse, second invasive non-breast primary tumor, or death due to any cause, whichever occurs first. In the event that none of the previous events were observed, censoring the last contact date will be considered.

PFS: it is defined as the time from the start date of a specific treatment to the documentation of disease progression on such treatment, or death due to any cause, whichever occurs first. In the event that none of the previous events were observed, censoring the last contact date will be considered.

OS: it is defined as the time from the date of initial breast cancer diagnosis to the date of death due to any cause.